Ceritinib
- TRADE NAME: Zykadia (Novartis)
- INDICATIONS: Anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer
- CLASS: Anaplastic lymphoma kinase (ALK) inhibitor
- HALF-LIFE: 41 hours
FDA APPROVAL DATE: 04/29/2014
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Alfentanil, Carbamazepine, Cyclosporine, CYP3A and CYP2C9 substrates, Dihydroergotamine, Ergotamine, Fentanyl, Grapefruit Juice, Ketoconazole, Nefazodone, Phenytoin, Pimozide, Quinidine, Rifampin, Ritonavir, Sirolimus, St John's Wort, Strong CYP3A inhibitors and inducers, Tacrolimus, Telithromycin, Warfarin
PREGNANCY CATEGORY: D
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.
Page last updated 12/07/2021
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
